Compound ID | 150
Class: Beta-lactam + beta-lactamase inhibitor
| Agent Type: | Semisynthetic; Small molecule; Direct acting; Indirect acting; Antibiotic adjuvant; |
| Spectrum of activity: | Gram-negative |
| Mechanism of action: | Cell wall synthesis inhibitor |
| Target Pathogen: | Active against metallo-beta-lactamase-producing Gram-negatives such as Enterobacteriaceae and Pseudomonas aeruginosa |
| Combined with other compounds: | Yes |
| Description: | A monobactam and a non-beta-lactam beta-lactamase inhibitor (diazabicyclooctane [DBO]) |
| Institute where first reported: | Pfizer Inc./Allergan PLC (formerly Actavis) |
| Year first mentioned: | 2012 |
| Highest developmental phase: | Phase 3 (NCT03329092) |
| Development status: | Active |
| Chemical structure(s): | |||||||||||||
|
|
||||||||||||
|
|
||||||||||||
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/5742832 |
| Guide to Pharmacology: | aztreonam |
| Citations: |
|